Phoenix—Immunotherapy has ushered in a new era of toxicity management for cancer patients, with those taking these new therapies able to avoid traditional chemotherapy-related adverse effects (AEs) but experiencing rare but serious immunotherapy-related AEs (irAEs).
In dealing with irAEs, “prompt management is the key to successful outcomes,” stressed Patrick Medina, PharmD, BCOP, a professor at the University of Oklahoma College of Medicine, in Oklahoma City. Once irAEs